Kelyniam Global, a medical device design and manufacturing company, announced it has acquired Med-Ally as part of its product diversification initiative.
Med-Ally applies custom, proprietary neuromodulation technology to create a number of external and implantable medical devices that can be used to treat an array of conditions, including chronic pain management, urinary incontinence, sleep apnea, tinnitus, and deep brain stimulation applications such as Alzheimer's disease, epilepsy, and Parkinson's disease.
Kelyniam's current product line is made up of precise and novel, customized polyetheretherketone (PEEK) cranial and facial implants used to fill bony voids caused by trauma, birth defects, or disease. Its streamlined CAD/CAM design and manufacturing techniques enable Kelyniam to deliver patient-specific PEEK implants to surgeons in as few as 24 hours from the receipt of an order, according to the company.
"Kelyniam's mission is to develop and manufacture medical devices that significantly improve medical care, surgical outcomes, and patient quality of life, and our acquisition of Med-Ally greatly enhances our ability to do just that," stated Tennyson Anthony, president and CEO of Kelyniam Global, in a press release.
